Good morning, welcome to the 2026 Annual Meeting of Shareholders for Imunon, Inc. At this time, all participants will be in a listen-only mode. I will now turn the call over to Susan Eylward, Imunon's Corporate Secretary. Good morning, welcome to Imunon's 2026 Annual Meeting of Shareholders. Except for historical information, certain statements made during this meeting are forward-looking statements involving significant risks and uncertainties. These risks and uncertainties, including those related to the future financial position and business strategy of the company, are detailed in the company's filings with the Securities and Exchange Commission. I would now like to introduce Mr. Michael Tardugno, the Executive Chairman of Imunon and its Board of Directors. Thank you, Susan. Good morning, ladies and gentlemen. As the Chairman of the Board of Imunon, it is my pleasure to welcome all of you to our 2026 Annual Meeting of Shareholders. Again, this year, we will be conducting a virtual annual meeting. After dialing into the meeting this morning, you should have been provided with a copy of our meeting agenda. It is our intention to conduct the meeting in accordance with this agenda. Only those individuals who are shareholders in Imunon as of the record date, that's 4/17/2026, are allowed to participate in this meeting of shareholders. I would like to note that, as is our long-held practice, we have provided time for questions at the end of the meeting. Before proceeding to the business portion of the meeting, I would like to introduce the company's directors and executive officers who are present with me and by phone today. Members of our Board of Directors are Dr. Donald Braun, Mr. James Dentzer, Mr. Frederick Fritz, Ms. Christine Pellizzari, and of course, our CEO, Dr. Stacy Lindborg. I would also like to introduce members of Imunon's executive staff. They include Dr. Stacy Lindborg, our President and Chief Executive Officer and Board Director, Dr. Douglas Faller, our Chief Medical Officer, Mr. Jeffrey Church, our interim Chief Financial Officer, and from whom you've just heard, Ms. Susan Eylward, our General Counsel and Corporate Secretary. Finally, I would like to note that Mr. Alexander Dundara, our Engagement Partner from WithumSmith+Brown, the company's independent public accountants, is also with us today. I would now like to ask Ms. Eylward to attend to certain procedural matters. Thank you. Susan? Thank you, Michael. This meeting is being held pursuant to the proxy statement mailed on May 4th, 2026, to each shareholder of record of the company at the close of business on April 17th, 2026, the record date fixed by the board of directors for determining the shareholders entitled to notice of and to vote at this meeting. I have a copy of the printed proxy statement dated May 4th, 2026, setting forth the time, place, and purpose of this meeting. I also have a complete list in alphabetical order of the record holders of our common stock as of the close of business on April 17th, 2026. The list shows the address for each shareholder and the number of shares registered in each shareholder's name. This list, which will be kept open for inspection throughout the meeting, shows that at the close of business on April 17th, 2026, there were 3,983,342 shares of Imunon common stock outstanding. I have an affidavit of distribution signed by Joanna Vogel, manager of Broadridge Financial Solutions, showing that commencing on May 4th, 2026, she caused to be mailed to each shareholder of record a copy of the proxy statement together with related proxy materials. I'll now turn it back to Michael. Ms. Eylward is directed to incorporate a copy of the proxy statement together with the affidavit of mailing into the minute book of the company as part of the minutes of this annual meeting. Prior to this meeting, the Board of Directors appointed Mr. Church as Inspector of Elections. He has executed the Oath of Inspector of Elections. We will file Mr. Church's oath with the meeting minutes of this meeting. Mr. Church will now conduct a poll of the shareholders represented here today in person or by proxy. Jeff? Thank you. There was a total of 3,983,342 shares of the company's common stock outstanding as of the record date. Pursuant to our bylaws, a quorum for conduct of business at this annual meeting requires the presence in person or by proxy of the holders of record of at least 33 and one-third% of their shares. I am advised that a total of 1,808,666 shares of Imunon's common stock, or 45.4% of the total outstanding shares, is present or represented by proxy here today. Having met the quorum requirements by the vote of sufficient issued and outstanding shares of common stock of the company entitled to vote at this meeting being present in person or represented by proxy, a quorum is present. I hereby declare the meeting to be lawfully and properly convened and competent to proceed to the transaction of the business for which it has been called, as stated in the meeting notice. On behalf of the board of directors, I would like to express my appreciation to all shareholders, and particularly those who are in attendance at this meeting today, and to those who have returned their proxies. It is one of my more gratifying tasks as chairman of your board of directors to thank you for your loyalty and for your continued support. On your behalf, I would like to express our gratitude to the company's board of directors, not only for their support and guidance, but also for their independence and commitment to its fiduciary responsibilities to our shareholders and to our employees. I want to turn the meeting over to Stacy Lindborg now, your President and Chief Executive Officer, for a brief business overview. Stacy? Thank you, Michael. Over the past year, Imunon has achieved several important and exceptionally meaningful clinical milestones. Our lead product candidate, IMNN-001, continues to make strong progress in the pivotal phase III OVATION 3 study, evaluating its potential as a frontline treatment for women newly diagnosed with advanced ovarian cancer. Enrollment continues to be ahead of plan, supported by strong interest from principal investigators and the medical community, with multiple sites activated across North America and the first patient dosed in July 2025. We are on track to complete enrollment by Q1 2029, with a clear regulatory path to a potential BLA filing aligned with the FDA. Our completed phase II OVATION 2 study delivered even more compelling final data announced in March 2026, showing a median increase of 14.7 months in overall survival, which was 45.1 months with the IMNN-001 experimental arm versus 30.4 months with the standard of care. Again, a median increase of 14.7 months over the standard of care in the intent-to-treat population, an improvement that continues to strengthen with longer follow-up. In the subgroup of patients who received PARP inhibitor treatment as maintenance therapy, the median overall survival benefit reached 24.2 months, which was 66.6 months in the IMNN-001 arm versus 41.4 months in the standard of care control arm. These results are especially powerful since there has never been a trial that has demonstrated an overall survival benefit in this patient population. IMNN-001 also maintained its highly favorable safety and tolerability profile. These data position Imunon as a potential transformative advance in the standard of care for a disease that has seen virtually no meaningful advances in frontline therapy in over 25 years. Furthermore, since Imunon is the first company to safely and successfully harness the power of IL-12 as an investigative therapy, if we are successful in phase III, IMNN-001 would be a first-in-class IL-12 immunotherapy, opening the door for potential advances well beyond ovarian cancer. Building on the strength of OVATION 2, the phase II results, the company presented trials and progress updates on the ongoing phase III, OVATION 3 study at two prestigious international oncology forums. At the European Society for Medical Oncology Congress in 2025, with an encore at the International Gynecologic Cancer Society, IGCS 2025 annual global meeting. Additional translational data from the phase II OVATION 2 study were presented at the Society for Immunotherapy of Cancer, or otherwise known as SITC, their 40th annual meeting, and key insights were shared during our November 2025 R&D Day. We'll soon be announcing plans for an R&D Day in Q3 2026, and we look forward to inviting you to hear from a panel of physicians and scientists who are intimately involved with our novel immunotherapy. With the pivotal phase III trial advancing, final phase II data reinforcing IMNN-001's potential, and a focused financial strategy, the company is poised for transformative growth. We remain fully dedicated to bringing IMNN-001 to patients fighting advanced ovarian cancer. The company has continued to demonstrate its ability to finance operations through creative, efficient, and shareholder-friendly routes that support the advancement of our clinical programs while extending our cash runway. As always, our goal is to finance the company while not forgetting our shareholders and keeping a sharp focus on our North Star, which is bringing an innovative and much-needed new treatment option to women with advanced ovarian cancer. Over the past year, Imunon has executed multiple financings, including a May 2025 private placement at the market under NASDAQ rules that provided $3.25 million in immediate gross proceeds, with the potential for an additional $6.5 million from short-term warrant exercises. In December of 2025, a registered direct offering that raised $7 million, also priced at the market, and as announced on June 4th, up to $10 million is expected in aggregate gross proceeds from a uniquely structured, flexible financing. These targeted actions, paired with rigorous expense management and a sharp focus on the OVATION 3 program, ensure that we remain well-positioned to fund key clinical milestones without compromising our momentum. Our approach to raising capital reflects our steadfast commitment to advancing IMNN-001 and creating long-term value for shareholders as we work to deliver this potentially transformative therapy to patients advancing ovarian cancer. With that, I'd like to turn the meeting back to Michael. Thank you, Stacy, not only for your encouraging comments but also for your fine stewardship of Imunon over this past year. As a preliminary matter, I would like to point out that most of you who have returned proxies authorizing the individuals named in the proxy to vote on all proposals coming before the meeting. Those of you who have signed into our virtual annual shareholder meeting requesting ballots can vote individually anytime during the meeting up until the polls are closed. The proxy statement mailed to each Imunon shareholder with the additional proxy materials indicated there will be four proposals to be acted upon today. The matters to be acted upon are these: the election of two Class I directors. That's Mr. Fritz and Ms. Pellizzari, each to serve until the annual meeting of shareholders in 2029. Second, a proposal to ratify the selection of WithumSmith+Brown as the company's independent public accountants for the fiscal year ending December 31, 2026. Third, a proposal to approve by non-binding advisory vote the 2025 executive compensation for the company's executive officers, and fourth, a proposal to approve an amendment to the Imunon, Inc. 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the plan. As indicated in the proxy statement, the board has nominated Mr. Fritz and Ms. Pellizzari to serve as Class I directors of the company under our classified board of directors. If elected, both Class I directors will serve until our annual meeting in 2029 or until their successors are elected and qualified. I would like to request a motion. Mr. Chairman, I hereby move for the election of Mr. Fritz and Ms. Pellizzari to serve as Class I directors of the company until the annual shareholders meeting in 2029 or until their successors have been elected and qualified, as set out in the company's proxy statement. You have heard a motion. Is there a second? I second the motion. The board recommends for the election of each of the Class I nominees for director, each to serve until the company's annual meeting of shareholders in 2029. Next on the agenda is ratification of the selection of WithumSmith+Brown to serve as our independent public accountants for the fiscal year ending December 31, 2026. I would like to request a motion. Mr. Chairman, I move that the appointment by the board of directors of WithumSmith+Brown to serve as Imunon's independent public accountants for the fiscal year ending December 31st, 2026, be ratified and approved by the shareholders of the company. You have heard the motion. Is there a second? I second the motion. The board recommends for the ratification of the appointment of WithumSmith+Brown to serve as Imunon's independent registered public accountants for the fiscal year ending December 31, 2026. Please remember that Mr. Alexander Dundara from Withum will have an opportunity to respond to any questions you have on the company's 2025 financial statements a little later in the meeting. Next item of business is to approve by a non-binding advisory vote the 2025 compensation program for the company's executive officers. I would like a motion, please. Mr. Chairman, I hereby move to approve by a non-binding advisory vote the 2025 compensation program for the company's executive officers. You have heard the motion. Is there a second? I second the motion. The board recommends for the approval of the 2025 executive compensation program. The next item of business is to approve an amendment to Imunon, Inc. 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the plan. I would like to request a motion. Mr. Chairman, I hereby move to approve an amendment to the Imunon, Inc. 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the plan. You have heard the motion. Is there a second? I second the motion. The board recommends for the approval of an amendment to the Imunon, Inc. 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the plan. If any shareholder would like to vote on these matters, I suggest that you vote your shares now. If you have already sent in your proxy, there is no need to cast a ballot unless you wish to change the selection that you made on your proxy. Proxy holders will vote your shares as indicated on the proxy that you have already provided to us. If there are any shareholders who desire to vote your shares but who have not yet voted, please do so now. After those shares are voted and accounted for, I will declare the polls closed. On behalf of my fellow directors and employees of Imunon, I want to thank you again for your past and continued support of the company. As the votes are being counted, we have some time available for any questions. If you want to discuss other matters for which there may not be time, we will be happy to talk with you individually after the meeting. Are there any questions? We do not have any questions at this time. Okay. There being none, proposal number 2. Susan, are you presenting the results? Jeff. Yes. Jeffrey Church, our inspector, will present them. Okay. Jeffrey, please. Yes. The inspector's report shows the following results. Proposal number one, election of Class I directors. Mr. Frederick Fritz, 647,890 votes for, 70,401 withheld. Ms. Christine Pellizzari, 653,302 shares for, 64,989 shares withheld. Having received at least a plurality of the votes cast at this meeting, with each director receiving over 90% of the votes cast, Mr. Fritz and Ms. Pellizzari have been reelected to the company's board of directors. Proposal number two, ratification of WithumSmith+Brown to serve as the company's independent public accountants for the current fiscal year ending December 31st, 2026. Votes for, 1,715,881. Votes against, 81,399. Votes abstaining, 11,386. The proposal to ratify the appointment of WithumSmith+Brown to serve as the company's independent public accountants for the fiscal year ending December 31st, 2026, having received an affirmative vote of a majority of the votes cast, over 95%, has been approved. Proposal three, approval by a non-binding advisory vote of the 2025 compensation program for the company's executive officers. The votes for, 580,096. The votes against total, 115,666. Votes abstaining total, 22,529. The proposal having received the affirmative vote of a majority of the votes cast, over 83%, have been approved. Lastly, proposal number four, approval of the amendment to the company's 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the plan. The votes for total, 562,622. The votes against total, 137,055. The votes abstaining total, 18,614. The proposal having received the affirmative vote of a majority of the votes cast, over 80%, has been approved. Thank you, Jeffrey. Thanks to all of you who cast your votes. Very encouraging support of the company. Is there any other business to come before this meeting? There being no further business, I will entertain a motion to adjourn. I move that this meeting be adjourned. Is there a second to this motion? I second the motion. A motion to adjourn has been made and seconded. There has been no objection. Therefore, this meeting is adjourned. Ladies and gentlemen, I want to thank you for your attendance today and for your continued support of our important research and development initiatives. Thank you again very, very much. This now concludes the 2026 Imunon annual shareholder meeting. Thank you for joining, and have a pleasant day